ORALMEDIC®  ||| S:0 E:11 ||| NNP
for  ||| S:11 E:15 ||| IN
treatment  ||| S:15 E:25 ||| NN
of  ||| S:25 E:28 ||| IN
aphthous  ||| S:28 E:37 ||| JJ
stomatitis--possible  ||| S:37 E:58 ||| JJ
side  ||| S:58 E:63 ||| NN
effects  ||| S:63 E:71 ||| NNS
with  ||| S:71 E:76 ||| IN
repeated  ||| S:76 E:85 ||| JJ
applications  ||| S:85 E:98 ||| NNS
ORALMEDIC®  ||| S:98 E:109 ||| VBP
( ||| S:109 E:110 ||| -LRB-
HybenX ||| S:110 E:116 ||| NNP
,  ||| S:116 E:118 ||| ,
Epien  ||| S:118 E:124 ||| NNP
Medical  ||| S:124 E:132 ||| NNP
Inc. ||| S:132 E:136 ||| NNP
,  ||| S:136 E:138 ||| ,
Minneapolis ||| S:138 E:149 ||| NNP
,  ||| S:149 E:151 ||| ,
MN ||| S:151 E:153 ||| NNP
,  ||| S:153 E:155 ||| ,
USA ||| S:155 E:158 ||| NNP
)  ||| S:158 E:160 ||| -RRB-
is  ||| S:160 E:163 ||| VBZ
a  ||| S:163 E:165 ||| DT
relatively  ||| S:165 E:176 ||| RB
recent  ||| S:176 E:183 ||| JJ
commercial  ||| S:183 E:194 ||| JJ
agent  ||| S:194 E:200 ||| NN
designated  ||| S:200 E:211 ||| VBN
for  ||| S:211 E:215 ||| IN
the  ||| S:215 E:219 ||| DT
treatment  ||| S:219 E:229 ||| NN
of  ||| S:229 E:232 ||| IN
recurrent  ||| S:232 E:242 ||| FW
aphthous  ||| S:242 E:251 ||| FW
stomatitis  ||| S:251 E:262 ||| FW
( ||| S:262 E:263 ||| -LRB-
RAS ||| S:263 E:266 ||| NNP
) ||| S:266 E:267 ||| -RRB-
.  ||| S:267 E:269 ||| .
It  ||| S:269 E:272 ||| PRP
has  ||| S:272 E:276 ||| VBZ
the  ||| S:276 E:280 ||| DT
potential  ||| S:280 E:290 ||| JJ
to  ||| S:290 E:293 ||| TO
safely  ||| S:293 E:300 ||| VB
and  ||| S:300 E:304 ||| CC
effectively  ||| S:304 E:316 ||| RB
reduce  ||| S:316 E:323 ||| VB
pain  ||| S:323 E:328 ||| NN
associated  ||| S:328 E:339 ||| VBN
with  ||| S:339 E:344 ||| IN
RAS ||| S:344 E:347 ||| NNP
.  ||| S:347 E:349 ||| .
We  ||| S:349 E:352 ||| PRP
present  ||| S:352 E:360 ||| RB
two  ||| S:360 E:364 ||| CD
patients  ||| S:364 E:373 ||| NNS
who  ||| S:373 E:377 ||| WP
used  ||| S:377 E:382 ||| VBD
ORALMEDIC®  ||| S:382 E:393 ||| CD
to  ||| S:393 E:396 ||| TO
reduce  ||| S:396 E:403 ||| VB
pain  ||| S:403 E:408 ||| NN
caused  ||| S:408 E:415 ||| VBN
by  ||| S:415 E:418 ||| IN
RAS  ||| S:418 E:422 ||| NNP
lesions ||| S:422 E:429 ||| NNS
.  ||| S:429 E:431 ||| .
Both  ||| S:431 E:436 ||| DT
patients  ||| S:436 E:445 ||| NNS
developed  ||| S:445 E:455 ||| VBN
side  ||| S:455 E:460 ||| NN
effects  ||| S:460 E:468 ||| NNS
presenting  ||| S:468 E:479 ||| VBG
as  ||| S:479 E:482 ||| IN
deep  ||| S:482 E:487 ||| JJ
ulcerations  ||| S:487 E:499 ||| NN
with  ||| S:499 E:504 ||| IN
a  ||| S:504 E:506 ||| DT
necrotic  ||| S:506 E:515 ||| JJ
base  ||| S:515 E:520 ||| NN
at  ||| S:520 E:523 ||| IN
the  ||| S:523 E:527 ||| DT
location  ||| S:527 E:536 ||| NN
where  ||| S:536 E:542 ||| WRB
ORALMEDIC®  ||| S:542 E:553 ||| NNP
has  ||| S:553 E:557 ||| VBZ
been  ||| S:557 E:562 ||| VBN
repeatedly  ||| S:562 E:573 ||| RB
applied  ||| S:573 E:581 ||| VBN
as  ||| S:581 E:584 ||| IN
pain  ||| S:584 E:589 ||| NN
did  ||| S:589 E:593 ||| VBD
not  ||| S:593 E:597 ||| RB
diminish  ||| S:597 E:606 ||| VB
after  ||| S:606 E:612 ||| IN
the  ||| S:612 E:616 ||| DT
first  ||| S:616 E:622 ||| JJ
application ||| S:622 E:633 ||| NN
.  ||| S:633 E:635 ||| .
One  ||| S:635 E:639 ||| CD
patient  ||| S:639 E:647 ||| NN
used  ||| S:647 E:652 ||| VBD
ORALMEDIC®  ||| S:652 E:663 ||| CD
several  ||| S:663 E:671 ||| JJ
times  ||| S:671 E:677 ||| NNS
on  ||| S:677 E:680 ||| IN
the  ||| S:680 E:684 ||| DT
same  ||| S:684 E:689 ||| JJ
lesion ||| S:689 E:695 ||| NN
.  ||| S:695 E:697 ||| .
However  ||| S:697 E:705 ||| RB
the  ||| S:705 E:709 ||| DT
other  ||| S:709 E:715 ||| JJ
patient  ||| S:715 E:723 ||| NN
followed  ||| S:723 E:732 ||| VBD
the  ||| S:732 E:736 ||| DT
manufacturer  ||| S:736 E:749 ||| NN
instructions  ||| S:749 E:762 ||| NNS
when  ||| S:762 E:767 ||| WRB
he  ||| S:767 E:770 ||| PRP
successively  ||| S:770 E:783 ||| VBP
used  ||| S:783 E:788 ||| VBN
ORALMEDIC®  ||| S:788 E:799 ||| RB
stick  ||| S:799 E:805 ||| VB
twice  ||| S:805 E:811 ||| RB
over  ||| S:811 E:816 ||| IN
the  ||| S:816 E:820 ||| DT
same  ||| S:820 E:825 ||| JJ
lesion ||| S:825 E:831 ||| NN
.  ||| S:831 E:833 ||| .
Patients  ||| S:833 E:842 ||| NNS
were  ||| S:842 E:847 ||| VBD
treated  ||| S:847 E:855 ||| VBN
with  ||| S:855 E:860 ||| IN
systemic  ||| S:860 E:869 ||| JJ
antibiotics  ||| S:869 E:881 ||| NN
and  ||| S:881 E:885 ||| CC
local  ||| S:885 E:891 ||| JJ
antiseptic  ||| S:891 E:902 ||| JJ
agents ||| S:902 E:908 ||| NNS
.  ||| S:908 E:910 ||| .
The  ||| S:910 E:914 ||| DT
healing  ||| S:914 E:922 ||| NN
process  ||| S:922 E:930 ||| NN
of  ||| S:930 E:933 ||| IN
the  ||| S:933 E:937 ||| DT
ulcers  ||| S:937 E:944 ||| NN
was  ||| S:944 E:948 ||| VBD
slow  ||| S:948 E:953 ||| JJ
and  ||| S:953 E:957 ||| CC
has  ||| S:957 E:961 ||| VBZ
completed  ||| S:961 E:971 ||| VBN
its  ||| S:971 E:975 ||| PRP$
course  ||| S:975 E:982 ||| NN
within  ||| S:982 E:989 ||| IN
six  ||| S:989 E:993 ||| CD
weeks ||| S:993 E:998 ||| NNS
.  ||| S:998 E:1000 ||| .
It  ||| S:1000 E:1003 ||| PRP
is  ||| S:1003 E:1006 ||| VBZ
suggested  ||| S:1006 E:1016 ||| VBN
that  ||| S:1016 E:1021 ||| IN
when  ||| S:1021 E:1026 ||| WRB
dental  ||| S:1026 E:1033 ||| JJ
surgeons  ||| S:1033 E:1042 ||| NNS
recommend  ||| S:1042 E:1052 ||| VBP
ORALMEDIC® ||| S:1052 E:1062 ||| RB
,  ||| S:1062 E:1064 ||| ,
they  ||| S:1064 E:1069 ||| PRP
should  ||| S:1069 E:1076 ||| MD
emphasize  ||| S:1076 E:1086 ||| VB
the  ||| S:1086 E:1090 ||| DT
importance  ||| S:1090 E:1101 ||| NN
of  ||| S:1101 E:1104 ||| IN
using  ||| S:1104 E:1110 ||| VBG
this  ||| S:1110 E:1115 ||| DT
agent  ||| S:1115 E:1121 ||| NN
according  ||| S:1121 E:1131 ||| VBG
to  ||| S:1131 E:1134 ||| TO
the  ||| S:1134 E:1138 ||| DT
manufacturer ||| S:1138 E:1150 ||| NN
's  ||| S:1150 E:1153 ||| POS
instructions  ||| S:1153 E:1166 ||| NNS
in  ||| S:1166 E:1169 ||| IN
order  ||| S:1169 E:1175 ||| NN
to  ||| S:1175 E:1178 ||| TO
minimize  ||| S:1178 E:1187 ||| VB
the  ||| S:1187 E:1191 ||| DT
risk  ||| S:1191 E:1196 ||| NN
for  ||| S:1196 E:1200 ||| IN
side  ||| S:1200 E:1205 ||| NN
effects ||| S:1205 E:1212 ||| NNS
.  ||| S:1212 E:1214 ||| .
